A newly published peer-reviewed study in BMC Public Health has found notable gaps in what people know about GLP-1 medications when using them for weight loss — a finding with broad relevance for the millions now taking drugs like Ozempic, Wegovy, Mounjaro, and Zepbound worldwide.
What the Study Examined
Researchers assessed the knowledge, attitudes, and real-world practices of Lebanese individuals using antidiabetic drugs — including GLP-1 receptor agonists — for weight loss purposes. The study, published in BMC Public Health, focused on whether people taking these medications truly understood how they work, what risks they carry, and how to use them safely and effectively. While the study population was based in Lebanon, the knowledge gaps identified reflect concerns that health professionals have raised globally as GLP-1 drugs surge in popularity beyond their original diabetes indications.
Why Knowledge Gaps Matter for GLP-1 Users
GLP-1 receptor agonists like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) work by mimicking gut hormones that regulate appetite, blood sugar, and digestion. They are powerful medications that require careful dosing and monitoring. When users lack accurate information about these drugs, the consequences can be significant:
- Improper dosing: Using incorrect doses — too high or too low — can undermine results or increase side effect risk.
- Missed warning signs: Users unaware of potential risks may not recognize symptoms that warrant medical attention.
- Unsupervised use: As demand outpaces supply, some people obtain GLP-1 drugs through channels that bypass medical oversight entirely.
- Unrealistic expectations: Misunderstanding how these medications work can lead to disappointment or misuse.
Key takeaway: Even motivated, health-conscious GLP-1 users may have significant gaps in their understanding of these medications — making regular, informed conversations with a prescriber essential, not optional.
What This Means If You're Taking a GLP-1 Drug
If you are currently taking or considering Ozempic, Wegovy, Mounjaro, or Zepbound, this research is a prompt to audit your own knowledge. Do you know what side effects to watch for and when to call your doctor? Do you understand that drugs originally approved for type 2 diabetes may carry different labeling and monitoring requirements when used for weight loss? Are you aware of how lifestyle factors like diet and exercise interact with these medications? These are not trivial questions — they are central to using GLP-1 therapy safely and getting the most out of it.
What to Watch Next
As GLP-1 medications continue to expand into new indications — including cardiovascular disease and sleep apnea — patient education will become even more critical. Researchers, regulators, and healthcare providers are increasingly focused on ensuring that the rapid adoption of these drugs is matched by adequate public understanding. Studies like this one in BMC Public Health help build the evidence base for better patient education programs and prescriber communication standards. More research examining knowledge and practice patterns in diverse populations is expected to follow.
Frequently Asked Questions
Research like this serves as a useful reminder that starting a GLP-1 medication is just the beginning — staying informed throughout your treatment is equally important. Always consult your prescriber or pharmacist with questions about your specific medication, dose, or health situation before making any changes to your treatment plan.
- Peer-reviewed journal article, 'Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population,' BMC Public Health.